Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 11/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18716626 | 0.88 | GAA (0.39) | GAACNR2DPP4HDAC2NPC1 | |
| SCHEMBL8248084 | 0.84 | KDM4E (0.41) | GAACNR2DPP4HDAC2NPC1 | |
| SCHEMBL8248045 | 0.79 | ALDH1A1 (0.38) | GAATSHRHDAC2NPC1ALDH1A1 | |
| SCHEMBL9965485 | 0.79 | SMN1; SMN2 (0.39) | GAADPP4HDAC2NPC1ALDH1A1 | |
| SCHEMBL18743854 | 0.78 | POLB (0.37) | GAATSHRHDAC2NPC1ALDH1A1 | |
| SCHEMBL24927033 | 0.78 | DPP4 (0.44) | GAADPP4HDAC2NPC1ALDH1A1 | |
| SCHEMBL5313764 | 0.77 | GAA (0.58) | GAATSHRDPP4HDAC1HDAC2 | |
| SCHEMBL24927603 | 0.76 | TSHR (0.44) | GAATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL28007107 | 0.75 | GAA (0.56) | GAATSHRDPP4HDAC1HDAC2 | |
| SCHEMBL28528638 | 0.75 | GAA (0.56) | GAATSHRDPP4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | GAA 1390/4885TSHR 1458/4885CNR2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.